お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
979405

次世代シーケンシング(NGS)検査:体外診断市場の分析および予測モデル

Next Generation Sequencing (NGS) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
次世代シーケンシング(NGS)検査:体外診断市場の分析および予測モデル
出版日: 2020年11月30日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の主要39カ国の次世代シーケンシング(NGS)検査の市場を調査し、市場および製品の概要、主な業界動向、インストールベース、新規販売数、平均販売価格などの各種データとその推移、製品の年間収益の推移と予測、競合環境と企業シェア、アナリストによる各種分析などをまとめています。

主な調査内容

  • 現在市販されている次世代シーケンシング(NGS)検査製品・競合情勢
  • 主要な業界動向のレビュー
  • 年間収益の推移・予測:各種区分別
    • 全ゲノムシーケンス解析
    • エクソームシーケンス解析
    • トランスクリプトームシーケンス(RNAシーケンス)解析
    • 複数遺伝子パネルのターゲットシーケンス解析
  • 各種詳細データ
    • インストールベース
    • 新規販売数
    • 平均販売価格、など
  • 企業シェア
  • アナリストによる分析

本書のメリット

  • パイプライン製品・技術をレビューし、ロバストパイプラインを持つ企業を特定することで、インライセンシング&アウトライセンシング戦略の構築・設計が可能に
  • 製品市場を形成・推進する動向を理解することで、事業戦略の構築が可能に
  • 主要動向、革新的製品&技術、影響力を持つ企業などについて理解を深めることで、収益の推進が可能に
  • 競合環境を理解し、市場リーダーのシェアを分析することで、有効な販売・マーケティング戦略の構築が可能に
  • 競合上優位に立つため、潜在力のある製品ポートフォリオを持つ新興企業を特定し、有効な対抗戦略を練ることが可能に
  • 世界・国別のデバイス売上の推移・予測の追跡が可能に
  • 統合・投資・戦略的提携の最大の機会を示す市場の区分・カテゴリーを特定することで、販売・マーケティングの取り組み活動の体系化が可能に
目次
Product Code: GDME703MM

Next Generation Sequencing (NGS) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on NGS Tests market for the year 2020 and beyond. NGS allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. NGS can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

It is now standard to test for a high number of mutations to personalize treatment decisions, use of NGS panels that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing. NGS is routinely being used to identify KRAS, BRAF, HER2 mutations.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Next Generation Sequencing (NGS) Tests and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Next Generation Sequencing (NGS) Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Next Generation Sequencing (NGS) Tests market.
  • Competitive dynamics insights and trends provided for Next Generation Sequencing (NGS) Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Agilent Technologies Inc, New England Biolabs Inc, and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

Who should buy this report?

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Next Generation Sequencing (NGS) Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Next Generation Sequencing (NGS) Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.